Contemporary surgical management of pediatric non‐rhabdomyosarcoma soft tissue sarcoma

Author:

Polites Stephanie F.1ORCID,Rhee Daniel S.2ORCID,Seitz Guido3,Dall'Igna Patrizia4ORCID,Binitie Odion5ORCID,Scharschmidt Thomas6,Lautz Timothy B.7ORCID,Dasgupta Roshni8ORCID

Affiliation:

1. Division of Pediatric Surgery Mayo Clinic Rochester Minnesota USA

2. Division of General Pediatric Surgery Department of Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA

3. Department of Pediatric Surgery and Urology University Hospital Giessen‐Marburg Giessen Germany

4. Department of Precision and Regenerative Medicine and Jonic Area (DiMePRe‐J) Azienda Ospedaliero‐Universitaria Consorziale Pediatric Hospital Giovanni XXIII Bari Italy

5. Department of Sarcoma Moffitt Cancer Center Tampa Florida USA

6. Department of Orthopedics James Cancer Hospital and Nationwide Children's Hospital Columbus Ohio USA

7. Division of Pediatric Surgery Ann & Robert H Lurie Children's Hospital of Chicago Northwestern University Chicago Illinois USA

8. Division of Pediatric General and Thoracic Surgery Cincinnati Children's Hospital Medical Center University of Cincinnati Cincinnati Ohio USA

Abstract

AbstractNon‐rhabdomyosarcoma soft tissue sarcoma (STS) comprises most STS in pediatric patients. It is a diverse set of over 30 histologic subtypes. Treatment is based on risk group determined by tumor size, grade, and the presence of metastases. Surgical resection is a cornerstone of therapy, as tumors are often resistant to chemotherapy or radiation. While patients with isolated tumors less than 5 cm may undergo upfront resection, strong consideration should be given to neoadjuvant chemoradiotherapy to ensure negative margins at surgical resection and optimal outcomes. Sentinel lymph node biopsy is strongly recommended for clear cell and epithelioid sarcomas. The most common metastatic site is the lung, and metastases should be resected at the end of therapy, when feasible. Unfortunately, many high‐risk patients progress on therapy, and alternative strategies including earlier metastatic control require investigation.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3